{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-007128","form_type":"8-K","ticker":"XBIT","cik":"0001626878","company_name":"XBiotech Inc.","filed_at":"2024-12-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.026482+00:00","generated_at":"2026-05-28T21:49:19.723315+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"XBiotech appoints renowned immunologist Dr. Tak W. Mak to its Board of Directors","bullets":["Dr. Mak appointed December 24, 2024 to fill board vacancy; will serve until next annual meeting.","Dr. Mak is a professor at University of Toronto, cloned T cell receptor (1984), and identified immune checkpoint CTLA-4.","He co-founded Agios Pharmaceuticals, which developed multiple FDA-approved cancer treatments.","Audit Committee remains two independent directors (McKenzie, Waldin); vacancy to be filled per Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-007128","json":"https://secwatch.observer/filing/0001171843-24-007128.json","markdown":"https://secwatch.observer/filing/0001171843-24-007128.md","text":"https://secwatch.observer/filing/0001171843-24-007128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626878/000117184324007128/0001171843-24-007128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626878/000117184324007128/f8k_123124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T21:49:19.723315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}